KOPIN CORP, 10-K filed on 3/14/2019
Annual Report
v3.19.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 29, 2018
Mar. 08, 2019
Jun. 30, 2018
Document And Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 29, 2018    
Document Fiscal Year Focus 2018    
Document Fiscal Period Focus FY    
Trading Symbol KOPN    
Entity Registrant Name KOPIN CORP    
Entity Central Index Key 0000771266    
Current Fiscal Year End Date --12-29    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   76,282,062  
Entity Public Float     $ 164,583,000
v3.19.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 29, 2018
Dec. 30, 2017
Current assets:    
Cash and cash equivalents $ 14,326,347 $ 24,848,227
Marketable debt securities, at fair value 22,918,016 43,907,457
Accounts receivable, net of allowance of $304,000 and $149,000 in 2018 and 2017, respectively 3,088,360 3,955,123
Contract assets and unbilled receivables 3,089,663 704,863
Inventory 4,797,238 5,080,797
Prepaid taxes 399,611 264,352
Prepaid expenses and other current assets 784,790 978,677
Total current assets 49,404,025 79,739,496
Property, plant and equipment, net 2,598,842 5,077,043
Goodwill 331,344 1,780,247
Intangibles 0 883,636
Other assets 1,649,401 3,842,068
Equity investments 5,565,499 0
Total assets 59,549,111 91,322,490
Current liabilities:    
Accounts payable 3,921,880 4,918,605
Accrued payroll and expenses 3,038,005 1,636,512
Accrued warranty 571,000 649,000
Contract liabilities and billings in excess of revenue earned 388,933 896,479
Other accrued liabilities 1,901,547 2,066,025
Income tax payable 0 1,416,892
Deferred tax liabilities 546,000 520,000
Total current liabilities 10,367,365 12,103,513
Contract liabilities, noncurrent 17,294 374,171
Asset retirement obligations 254,098 269,877
Other long-term liabilities 1,197,533 1,195,082
Commitments and contingencies (Note 12)
Stockholders’ equity:    
Preferred stock, par value $.01 per share: authorized, 3,000 shares; none issued 0 0
Common stock, par value $.01 per share: authorized, 120,000,000 shares; issued 80,735,320 shares in 2018 and 80,201,313 shares in 2017; outstanding 74,008,815 in 2018 and 73,058,783 in 2017, respectively 785,220 775,720
Additional paid-in capital 335,692,879 331,119,340
Treasury stock (4,513,256 shares in 2018 and 2017, at cost) (17,238,669) (17,238,669)
Accumulated other comprehensive income 1,554,587 3,564,779
Accumulated deficit (272,932,143) (240,121,901)
Total Kopin Corporation stockholders’ equity 47,861,874 78,099,269
Noncontrolling interest (149,053) (719,422)
Total stockholders’ equity 47,712,821 77,379,847
Total liabilities and stockholders’ equity $ 59,549,111 $ 91,322,490
v3.19.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
Dec. 29, 2018
Dec. 30, 2017
Accounts receivable, allowance $ 304,000 $ 149,000
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, authorized 3,000 3,000
Preferred stock, issued 0 0
Common stock, par value $ 0.01 $ 0.01
Common stock, authorized 120,000,000 120,000,000
Common stock, issued 80,735,320 80,201,313
Common stock, outstanding 74,008,811 73,058,783
Treasury stock, shares 4,513,256 4,513,256
v3.19.1
CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
12 Months Ended
Dec. 29, 2018
Dec. 30, 2017
Dec. 31, 2016
Revenues:      
Total revenues $ 24,465,005 $ 27,841,490 $ 22,642,566
Research and development and other revenues 5,253,890 2,946,685 1,527,441
Expenses:      
Cost of product revenues 15,831,441 18,118,418 17,814,271
Research and development-funded programs 4,892,066 3,364,658 786,867
Research and development-internal 12,553,237 15,515,057 15,252,794
Selling, general and administrative 27,210,849 20,541,244 16,961,773
Impairment of goodwill 1,417,470 600,086 0
Impairment of assets 2,526,669    
Gain on sale of property, plant and equipment   0 (7,700,522)
Total expenses 64,431,732 58,139,463 43,115,183
Loss from operations (39,966,727) (30,297,973) (20,472,617)
Non-operating income (expense), net:      
Interest income 640,059 775,626 658,384
Other income (expense), net 855,106 247,291 (448,581)
Foreign Currency Transaction Gain (Loss), Unrealized (166,829) (1,068,059) (672,727)
Gain on investments 2,849,816 2,000,000 1,034,396
Impairment of equity and cost investments (1,417,470) (600,086)  
Total other income and expense 4,178,152 1,954,858 571,472
Loss before benefit (provision) for income taxes and net loss (income) of noncontrolling interest (35,788,575) (28,343,115) (19,901,145)
Income Tax Expense (Benefit) (30,000) 2,963,000 (3,130,000)
Net loss (35,818,575) (25,380,115) (23,031,145)
Net (income) loss attributable to the noncontrolling interest (51,050) 139,633 (402,971)
Net loss attributable to Kopin Corporation $ (35,869,625) $ (25,240,482) $ (23,434,116)
Net loss per share:      
Basic and diluted (in dollars per share) $ (0.49) $ (0.36) $ (0.37)
Weighted average number of common shares outstanding:      
Basic and diluted (in shares) 73,156,545 69,914,956 64,045,675
Product [Member]      
Revenues:      
Total revenues $ 19,211,115 $ 24,894,805 $ 21,115,125
Expenses:      
Cost of product revenues 15,831,441    
Non-operating income (expense), net:      
Net loss attributable to Kopin Corporation $ (35,869,625)    
v3.19.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statement - USD ($)
12 Months Ended
Dec. 29, 2018
Dec. 30, 2017
Dec. 31, 2016
Statement of Comprehensive Income [Abstract]      
Net loss $ (35,818,575) $ (25,380,115) $ (23,031,145)
Other comprehensive income (loss), net of tax:      
Foreign currency translation adjustments (1,912,427) 1,921,655 809,099
Unrealized holding (loss) gain on marketable securities (264,949) 148,520 33,464
Reclassifications of gain (loss) in net loss 49,525 (6,376) (48,284)
Other comprehensive (loss) income, net of tax (2,127,851) 2,063,799 794,279
Comprehensive loss (37,946,426) (23,316,316) (22,236,866)
Comprehensive loss (income) attributable to the noncontrolling interest 66,609 69,642 (398,051)
Comprehensive loss attributable to Kopin Corporation $ (37,879,817) $ (23,246,674) $ (22,634,917)
v3.19.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total Kopin Corporation Stockholders' Equity
Noncontrolling Interest
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   736,842            
Beginning Balance (in shares) at Dec. 26, 2015   76,079,643            
Beginning Balance at Dec. 26, 2015 $ 94,484,780 $ 760,797 $ 326,558,527 $ (42,741,551) $ 771,774 $ (190,608,671) $ 94,740,876 $ (256,096)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Vesting of restricted stock   $ 7,368 (7,368)          
Stock-based compensation expense 2,482,326   2,482,326       2,482,326  
Other comprehensive income (loss) 794,279       799,197   799,197 (4,918)
Restricted stock for tax withholding obligations (in shares)   (175,542)            
Restricted stock for tax withholding obligations (510,597) $ (1,756) (508,841)       (510,597)  
Net income (loss) (23,031,145)         (23,434,116) (23,434,116) 402,971
Ending Balance (in shares) at Dec. 31, 2016   76,640,943            
Ending Balance at Dec. 31, 2016 74,219,643 $ 766,409 328,524,644 (42,741,551) 1,570,971 (214,042,787) 74,077,686 141,957
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   1,170,847            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Vesting of restricted stock   $ 11,708 (11,708)          
Stock-based compensation expense 3,375,330   3,375,330       3,375,330  
Other comprehensive income (loss) 2,063,799       1,993,808   1,993,808 69,991
Restricted stock for tax withholding obligations (in shares)   (239,752)            
Restricted stock for tax withholding obligations (771,323) $ (2,397) (768,926)       (771,323)  
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders (791,737)             (791,737)
Sale of unregistered stock 24,664,250     25,502,882   (838,632) 24,664,250  
Net income (loss) (25,380,115)         (25,240,482) (25,240,482) (139,633)
Ending Balance (in shares) at Dec. 30, 2017   77,572,038            
Ending Balance at Dec. 30, 2017 77,379,847 $ 775,720 331,119,340 (17,238,669) 3,564,779 (240,121,901) 78,099,269 (719,422)
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   1,093,000            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Vesting of restricted stock   $ 10,930 (10,930)          
Stock-based compensation expense 4,791,054   4,791,054       4,791,054  
Other comprehensive income (loss) (2,127,851)       (2,010,192)     (117,659)
Restricted stock for tax withholding obligations (in shares)   (142,972)            
Restricted stock for tax withholding obligations (208,015) $ (1,430) (206,585)       (208,015)  
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders (636,978)             (636,978)
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification 3,059,383         3,059,383 3,059,383  
Net income (loss) (35,818,575)         (35,869,625) (35,869,625) 51,050
Ending Balance (in shares) at Dec. 29, 2018   78,522,066            
Ending Balance at Dec. 29, 2018 $ 47,712,821 $ 785,220 $ 335,692,879 $ (17,238,669) $ 1,554,587 $ (272,932,143) $ 47,861,874 $ (149,053)
v3.19.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Dec. 29, 2018
Dec. 30, 2017
Dec. 31, 2016
Cash flows from operating activities:      
Net loss $ (35,818,575) $ (25,380,115) $ (23,031,145)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 1,958,680 2,501,891 993,621
Accretion of premium or discount on marketable debt securities 15,948 41,364 130,032
Stock-based compensation 4,791,054 2,296,131 2,425,326
Net gain on investment transactions (2,849,816) (2,000,000) (1,034,396)
Deferred income taxes 4,185 (2,421,040) 1,451,858
Foreign currency losses 177,469 893,260 711,356
Loss (gain) on sale of property and plant 51,159   (7,700,522)
Impairment of assets 2,526,669    
Impairment of goodwill 1,417,470 600,086  
Change in allowance for bad debt (155,000) 13,000 (17,000)
Other non-cash items 832,615 654,694 677,330
Change in warranty reserves (79,633) 142,328 0
Changes in assets and liabilities:      
Accounts receivable 853,163 (2,376,593) (39,629)
Contract assets and unbilled receivables 865,474    
Inventory (1,656,196) (1,633,027) (1,527,602)
Prepaid expenses, other current assets and other assets 113,015 (1,084,146) 48,295
Accounts payable and accrued expenses (1,208,848) 1,924,751 1,163,586
Billings in excess of revenue earned (4,742) (85,282) (425,805)
Net cash used in operating activities (28,165,909) (25,912,698) (26,174,695)
Cash flows from investing activities:      
Proceeds from sale of marketable debt securities 26,646,078 37,536,004 50,835,253
Purchase of marketable debt securities (5,697,329) (19,633,903) (51,828,988)
Proceeds from sale of investments 0 0 1,034,396
Cash paid for acquisition, net of cash acquired (1,000,000) (3,690,047)  
Proceeds from sale of III-V product line 0 0 15,000,000
Proceeds from sale of property and plant 0 0 8,106,819
Other assets (8,373) (140,860) 80,793
Capital expenditures (1,183,131) (2,794,467) (394,897)
Net cash provided by investing activities 18,757,245 11,276,727 22,833,376
Cash flows from financing activities:      
Sale of unregistered stock   24,664,250  
Settlements of restricted stock for tax withholding obligations (208,015) (771,323) (510,597)
Distribution to noncontrolling interest holder (636,978) (791,737)  
Net cash (used in) provided by financing activities (844,993) 23,101,190 (510,597)
Effect of exchange rate changes on cash (268,223) 560,513 (93,478)
Net (decrease) increase in cash and cash equivalents (10,521,880) 9,025,732 (3,945,394)
Cash and cash equivalents at beginning of year 24,848,227 15,822,495 19,767,889
Cash and cash equivalents at end of year 14,326,347 24,848,227 15,822,495
Supplemental disclosure of cash flow information:      
Income taxes paid 1,374,000 281,000 723,000
Construction in progress included in accrued expenses $ 0 $ 212,000 $ 0
v3.19.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 29, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
 Summary of Significant Accounting Policies
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. As used in these notes, the terms “we,” “us,” “our,” “Kopin” and the “Company” mean Kopin Corporation and its subsidiaries, unless the context indicates another meaning.
Going Concern
The Company has incurred net losses of $35.8 million, $25.4 million and $23.0 million for the fiscal years ended 2018, 2017 and 2016, respectively, and net cash outflows from operations of $28.2 million, $25.9 million and $26.2 million for the fiscal years ended 2018, 2017 and 2016, respectively. In addition, the Company has continued to experience a significant decline in its cash and cash equivalents and marketable debt securities, which was primarily a result of funding operating losses, of which a significant component relates to the Company’s ongoing investments in the research and development of Wearable products. These negative financial conditions raise substantial doubt regarding the Company’s ability to continue as a going concern.
The Company’s products are targeted towards the wearable market, which management believes is still developing and cannot predict how long the wearable market will take to develop or if the Company’s products will be accepted.  Accordingly, the Company’s current strategy is to continue to invest in research and development, even during unprofitable periods, which may result in the Company continuing to incur net losses and negative cash flows from operations.  If the Company is unable to achieve and maintain positive cash flows and profitability in the foreseeable future, its financial condition may ultimately be materially adversely affected such that management may be required to reduce operating expenses, including investments in research and development, or raise additional capital. While there can be no assurance the Company will be able to successfully reduce operating expenses or raise additional capital, management believes its historical success in managing cash flows and obtaining capital will continue in the foreseeable future.
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Fiscal Year
The Company’s fiscal year ends on the last Saturday in December. The fiscal years ended December 29, 2018 and December 30, 2017 includes 52 weeks and December 31, 2016 includes 53 weeks, and are referred to as fiscal years 2018, 2017 and 2016, respectively, herein. The impact of the 53rd week in the 2016 fiscal year was not material to the Company's results of operations.
Principles of Consolidation
The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and a majority owned 80% subsidiary, eMDT America Inc. ("eMDT"), located in California (collectively the Company). Net loss attributable to noncontrolling interest in the Company's Consolidated Statement of Operations represents the portion of the results of operations of which is allocated to the shareholders of the equity interests not owned by the Company. All intercompany transactions and balances have been eliminated.
Revenue Recognition - 2018
The Company adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) effective December 31, 2017 and applied the modified retrospective method. The Company recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of accumulated deficit. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The Company expects the impact of the adoption of the new standard to be material to the Company's results of operations on an ongoing basis. Significant changes to the Company's accounting policies as a result of adopting Topic 606 are discussed below.
Substantially all of our product revenues are either derived from the sales of components for use in military applications or our wearable technology components that can be integrated to create industrial and consumer headset systems. We also have development contracts for the design, manufacture and modification of products for the U.S. government or a prime contractor for the U.S. government or for a customer that sells into the industrial or consumer markets. The Company's contracts with the U.S. government are typically subject to the Federal Acquisition Regulations (“FAR”) and are priced based on estimated or actual costs of producing goods. The FAR provides guidance on the types of costs that are allowable in establishing prices for goods provided under U.S. government contracts. The pricing for non-U.S. government contracts is based on the specific negotiations with each customer.
Our fixed-price contracts with the U.S. government or other customers may result in revenue recognized in excess of amounts currently billed. We disclose the excess of revenues over amounts actually billed as Contract assets and unbilled receivables on the balance sheet. Amounts billed and due from our customers are classified as Accounts receivable on the balance sheets. In some instances, the U.S. government retains a small portion of the contract price until completion of the contract. The portion of the payments retained until final contract settlement is not considered a significant financing component because the intent is to protect the customer. For contracts with the U.S. government, we typically receive interim payments either as work progresses or by achieving certain milestones or based on a schedule in the contract. We recognize a liability for these advance payments in excess of revenue recognized and present it as Contract liabilities and billings in excess of revenue earned on the balance sheets. The advanced payment typically is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. For industrial and consumer purchase orders, we typically receive payments within 30 to 60 days of shipments of the product, although for some purchase orders, we may require an advanced payment prior to shipment of the product.
To determine the proper revenue recognition method for contracts with the same customer, we evaluate whether two or more contracts should be combined and accounted for as one single contract and whether the combined or single contract should be accounted for as more than one performance obligation. For most of our development contracts and contracts with the U.S government, the customer contracts with us to provide a significant service of integrating a set of components into a single unit. Hence, the entire contract is accounted for as one performance obligation. Less frequently, however, we may promise to provide distinct goods or services within a contract in which case we separate the contract into more than one performance obligation. If a contract is separated into more than one performance obligation, we allocate the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. In cases where we sell standard products, the observable standalone sales are used to determine the standalone selling price.
The Company recognizes revenue from a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.
Commencing in 2018 for certain contracts with the U.S. government, the Company recognizes revenue over time as we perform because of continuous transfer of control to the customer and the lack of an alternative use for the product. The continuous transfer of control to the customer is supported by liability clauses in the contract that allow the U.S. government to unilaterally terminate the contract for convenience, pay us for costs incurred plus a reasonable profit and take control of any work in process. For contracts with commercial customers, while the contract may have a similar liability clause, our products historically have an alternative use and thus, revenue is recognized at a point in time.
In situations where control transfers over time, revenue is recognized based on the extent of progress towards completion of the performance obligation. We generally use the cost-to-cost approach to measure the extent of progress towards completion of the performance obligation for our contracts because we believe it best depicts the transfer of assets to the customer. Under the cost-to-cost measure approach, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. Revenues are recorded proportionally as costs are incurred.
Accounting for design, development and production contracts requires judgment relative to assessing risks, estimating contract revenues and costs, and making assumptions for schedule and technical issues. Due to the size and nature of the work required to be performed on many of our contracts, the estimation of total revenue and cost at completion is complicated and subject to many variables. Contract costs include material, labor and subcontracting costs, as well as an allocation of indirect costs. We have to make assumptions regarding the number of labor hours required to complete a task, the complexity of the work to be performed, the availability and cost of materials, and performance by our subcontractors. For contract change orders, claims or similar items, we apply judgment in estimating the amounts and assessing the potential for realization. These amounts are only included in contract value when they can be reliably estimated and realization is considered probable. If our estimate of total contract costs or our determination of whether the customer agrees that a milestone is achieved is incorrect, our revenue could be overstated or understated and the profits or loss reported could be subject to adjustment.
For our commercial customers, the Company's revenue is recognized when obligations under the terms of a contract with our customer is satisfied and the Company transfers control of the products or services, which is generally upon delivery to the customer. Revenue is recorded as the amount of consideration we expect to receive in exchange for transferring goods or providing services. Provisions for product returns and allowances are reductions in the transaction price and are recorded in the same period as the related revenues. We analyze historical returns, current economic trends and changes in customer demand when evaluating the adequacy of sales returns and other allowances. Certain product sales are made to distributors under agreements allowing for a limited right of return on unsold products. Sales to distributors are primarily made for sales to the distributors' customers and not for stocking of inventory. Sales, value add and other taxes we collect concurrent with revenue-producing activities are excluded from revenue.
The rights and benefits to the Company's intellectual property are conveyed to certain customers through technology license agreements. These agreements may include other performance obligations including the sale of product to the customer. When the license is distinct from other obligations in the agreement, the Company treats the license and other performance obligations as separate performance obligations. Accordingly, the license is recognized at a point in time or over time based on the standalone selling price. The sale of materials is recognized at a point in time, which occurs with the transfer of control of the Company's products or services. In certain instances, the Company is entitled to sales-based royalties under license agreements. These sales-based royalties are recognized when they are earned. Revenues from sales-based royalties under license agreements are shown under Research and development and other revenues on the Company's Consolidated Statements of Operations.
The cumulative effect of the changes made to the Company's consolidated December 31, 2017 balance sheet for the adoption of ASU 2014-09, Revenue from Contracts with Customers (Topic 606) was as follows:
Balance Sheet
Balance at December 30, 2017
 
Adjustments due to Topic 606
 
Balance at December 31, 2017
Assets
 
 
 
 
 
Contract assets and unbilled receivables
$
704,863

 
$
2,850,274

 
$
3,555,137

Inventory
5,080,797

 
(1,082,629
)
 
3,998,168

Other assets
3,842,068

 
400,000

 
4,242,068

 
 
 
 
 
 
Liabilities
 
 
 
 
 
Contract liabilities and billings in excess of revenue earned
1,555,883

 
(891,737
)
 
664,146

 
 
 
 
 
 
Stockholders’ equity
 
 
 
 
 
Accumulated Deficit
$
(240,121,901
)
 
$
3,059,383

 
$
(237,062,519
)
In accordance with the new revenue standard requirements, the impact of adoption on the Company's consolidated statement of operations for the fiscal year 2018 was as follows:
Statement of Operations
As Reported
 
Balances Without Adoption of
Topic 606
 
Effect of Change Higher/(Lower)
Net product revenues
$
19,211,115

 
$
19,726,901

 
$
(515,786
)
Research and development and other revenues
5,253,890

 
5,600,066

 
(346,176
)
Cost of product revenues
15,831,441

 
16,809,343

 
(977,902
)
Net loss attributable to Kopin Corporation
$
(35,869,625
)
 
$
(35,985,565
)
 
$
115,940


See Note 14. Segments and Disaggregation of Revenue for additional information regarding the disaggregation of the Company's revenue by major source.
Contract Assets
Contract assets include unbilled amounts typically resulting from sales under contracts when the cost-to-cost method of revenue recognition is utilized and revenue recognized from customer arrangements, including licensing, exceeds the amount billed to the customer, and right to payment is not just subject to the passage of time. Amounts may not exceed their net realizable value. Contract assets are generally classified as current. The Company classifies the noncurrent portion of contract assets under other assets in its condensed consolidated balance sheets.
Contract Liabilities
Contract liabilities consist of advance payments and billings in excess of revenue recognized for the contract.
Performance Obligations
The Company's revenue recognition related to performance obligations that were satisfied at a point in time and over time were as follows:
Fiscal year ended
2018
 
2017
 
2016
Point in time
60
%
 
91
%
 
95
%
Over time
40
%
 
9
%
 
5
%

The value of remaining performance obligations represent the transaction price of orders for which work has not been performed and excludes unexercised contract options and potential orders under ordering-type contracts (e.g., indefinite-delivery, indefinite-quantity ("IDIQ")). As of December 29, 2018, the aggregate amount of the transaction price allocated to remaining performance obligations was $8.0 million. The Company expects to recognize revenue on the remaining performance obligations of $8.0 million over the next 12 months. The remaining performance obligations represent amounts to be earned under government contracts, which are subject to cancellation.
Revenue Recognition - 2017
We recognize revenue if four basic criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and services rendered; (3) the price to the buyer is fixed or determinable; and (4) collectability is reasonably assured. We do not recognize revenue for products prior to customer acceptance unless we believe the product meets all customer specifications and has a history of consistently achieving customer acceptance of the product. Provisions for product returns and allowances are recorded in the same period as the related revenues. We analyze historical returns, current economic trends and changes in customer demand and acceptance of product when evaluating the adequacy of sales returns and other allowances. Certain product sales are made to distributors under agreements allowing for a limited right of return on unsold products. Sales to distributors are primarily made for sales to the distributors' customers and not for stocking of inventory. We delay revenue recognition for our estimate of distributor claims of right of return on unsold products based upon our historical experience with our products and specific analysis of amounts subject to return based upon discussions with our distributors or their customers.
We recognize revenues from long-term research and development government contracts on the percentage-of-completion method of accounting as work is performed, based upon the ratio of costs or hours already incurred to the estimated total cost of completion or hours of work to be performed. Revenue recognized at any point in time is limited to the amount funded by the U.S. government or contracting entity. We recognize revenue for product development and research contracts that have established prices for distinct phases when delivery and acceptance of the deliverable for each phase has occurred. In some instances, we are contracted to create a deliverable which is anticipated to go into full production. In those cases, we discontinue the percentage-of-completion method after formal qualification of the deliverable has been completed and revenue is then recognized based on the criteria established for sale of products. In certain instances, qualification may be achieved and delivery of production units may commence however our customer may have either identified new issues to be resolved or wish to incorporate a newer display technology. In these circumstances new units delivered will continue to be accounted for under the criteria established for sale of products. Under certain of our research and development contracts, we recognize revenue using a milestone methodology. This revenue is recognized when we achieve specified milestones based on our past performance.
We classify amounts earned on contracts in progress that are in excess of amounts billed as unbilled receivables and we classify amounts received in excess of amounts earned as billings in excess of revenues earned. We invoice based on dates specified in the related agreement or in periodic installments based upon our invoicing cycle. We recognize the entire amount of an estimated ultimate loss in our financial statements at the time the loss on a contract becomes known.
Accounting for design, development and production contracts requires judgment relative to assessing risks, estimating contract revenues and costs, and making assumptions for schedule and technical issues. Due to the size and nature of the work required to be performed on many of our contracts, the estimation of total revenue and cost at completion is complicated and subject to many variables. Contract costs include material, labor and subcontracting costs, as well as an allocation of indirect costs. We have to make assumptions regarding the number of labor hours required to complete a task, the complexity of the work to be performed, the availability and cost of materials, and performance by our subcontractors. For contract change orders, claims or similar items, we apply judgment in estimating the amounts and assessing the potential for realization. These amounts are only included in contract value when they can be reliably estimated and realization is considered probable. We have accounting policies in place to address these as well as other contractual and business arrangements to properly account for long-term contracts. If our estimate of total contract costs or our determination of whether the customer agrees that a milestone is achieved is incorrect, our revenue could be overstated and profits would be negatively impacted.
Research and Development Costs
Research and development expenses are incurred in support of internal display product development programs or programs funded by agencies or prime contractors of the U.S. government and commercial partners. Research and development costs include staffing, purchases of materials and laboratory supplies, circuit design costs, fabrication and packaging of experimental display products, and overhead, and are expensed immediately.
Cash and Cash Equivalents
The Company considers all highly liquid, short-term debt instruments with original maturities of three months or less to be cash equivalents.
Inventory
Inventories are stated at standard cost adjusted to approximate the lower of cost (first-in, first-out method) or net realizable value. The Company adjusts inventory carrying value for estimated obsolescence equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. The Company fully reserves for inventories and non-cancellable purchase orders for inventory deemed obsolete. The Company performs periodic reviews of inventory items to identify excess inventories on hand by comparing on-hand balances to anticipated usage using recent historical activity as well as anticipated or forecasted demand. If estimates of customer demand diminish further or market conditions become less favorable than those projected by the Company, additional inventory adjustments may be required.
We regularly review inventory quantities on-hand and we write down inventory based on excess or obsolete inventories determined primarily by future anticipated demand for our products. Inventory write-downs are measured as the difference between the cost of the inventory and net realizable value, based upon assumptions about future demand, which are inherently difficult to assess and dependent on market conditions. At the point of a loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established basis.
Inventory consists of the following at December 29, 2018 and December 30, 2017:
 
2018
 
2017
Raw materials
$
2,548,139

 
$
2,070,153

Work-in-process
1,526,552

 
1,829,805

Finished goods
722,547

 
1,180,839

 
$
4,797,238

 
$
5,080,797


Property, Plant and Equipment
Property, plant and equipment are recorded at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the assets, generally 3 to 10 years. Leasehold improvements and leased equipment are amortized over the shorter of the term of the lease or the useful life of the improvement or equipment. As discussed below, obligations for asset retirement are accrued at the time property, plant and equipment is initially purchased or as such obligations are generated from use.
Collaborative Arrangements
The Company evaluates whether an arrangement is a collaborative arrangement under the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 808Collaborative Arrangements, at its inception based on the facts and circumstances specific to the arrangement. The Company also reevaluates whether an arrangement qualifies or continues to qualify as a collaborative arrangement whenever there is a change in either the roles of the participants or the participants’ exposure to significant risks and rewards dependent on the ultimate commercial success of the endeavor. For those collaborative arrangements where it is determined that the Company is the principal participant, costs incurred and revenue generated from third parties are recorded on a gross basis in the financial statements.
From time to time, the Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of products. The Company’s collaboration agreements with third parties are performed on a ‘‘best efforts’’ basis with no guarantee of either technological or commercial success.
Product Warranty
The Company generally sells products with a limited warranty of product quality and a limited indemnification of customers against intellectual property infringement claims related to the Company’s products. The Company accrues for known warranty and indemnification issues if a loss is probable and can be reasonably estimated, and accrues for estimated incurred but unidentified issues based on historical activity. Accrued warranty costs and warranty claims are not material in the periods presented.
Extended Warranties
The Company recognizes revenue from an extended warranty on the straight-line method over the life of the extended warranty, which is typically 12 to 18 months beyond the standard 12 month warranty. The Company classifies the current portion of extended warranties under contract liabilities and billings in excess of revenue earned and the noncurrent portion of extended warranties under contract liabilities, noncurrent in its consolidated balance sheets. The Company currently has approximately $0.4 million of contract liabilities related to extended warranties at December 29, 2018.
Asset Retirement Obligations
The Company recorded asset retirement obligations ("ARO") liabilities of $0.3 million at December 29, 2018 and December 30, 2017. This represents the legal obligations associated with retirement of the Company’s assets when the timing and/or method of settling the obligation are conditional on a future event that may or may not be within the control of the Company. Changes in ARO liabilities for fiscal years 2018 and 2017 are as follows:
 
2018
 
2017
Beginning balance
$
269,877

 
$
246,922

Exchange rate change
(15,779
)
 
22,955

Ending balance
$
254,098

 
$
269,877


Income Taxes
The consolidated financial statements reflect provisions for federal, state, local and foreign income taxes. The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as operating loss and tax credit carryforwards. The Company measures deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company provides valuation allowances if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

Foreign Currency
Assets and liabilities of non-U.S. operations where the functional currency is other than the U.S. dollar are translated from the functional currency into U.S. dollars at year end exchange rates, and revenues and expenses are translated at average rates prevailing during the year. Resulting translation adjustments are accumulated as part of accumulated other comprehensive income. Transaction gains or losses are recognized in income or loss in the period in which they occur.
Net Loss Per Share
Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period less any unvested restricted shares. Diluted net loss per share is calculated using weighted-average shares outstanding and contingently issuable shares, less weighted-average shares reacquired during the period. The net outstanding shares are adjusted for the dilutive effect of shares issuable upon the assumed conversion of the Company’s common stock equivalents, which consist of outstanding stock options and unvested restricted stock.
The following were not included in weighted-average common shares outstanding-diluted because they are anti-dilutive or performance conditions have not been met at the end of the period:
 
2018
 
2017
 
2016
Nonvested restricted common stock
2,213,249

 
2,629,274

 
3,007,674


Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentration of credit risk other than marketable securities consist principally of trade accounts receivable. Trade receivables are primarily derived from sales to manufacturers of consumer electronic devices and wireless components or military applications. The Company sells its products to customers worldwide and generally does not require collateral. The Company maintains a reserve for potential credit losses.
The Company primarily invests its excess cash in government backed and corporate debt securities that management believes to be of high credit worthiness, which bear lower levels of relative credit risk. The Company relies on rating agencies to ascertain the credit worthiness of its marketable securities and, where applicable, guarantees made by the Federal Deposit Insurance Company.
Fair Value of Financial Instruments
Financial instruments consist of marketable debt securities, accounts receivable and certain current liabilities. These assets (excluding marketable securities which are recorded at fair value) and liabilities are carried at cost, which approximates fair value.
Recognition and Measurement of Financial Assets and Liabilities
We periodically make equity investments in private companies, accounted for as an equity investment, whose values are difficult to determine. The Company adopted ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities and the related amendments on December 31, 2017. This standard amends various aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The Company adopted the measurement alternative for equity investments without readily determinable fair values (often referred to as cost method investments) on a prospective basis. When assessing investments in private companies for impairment, we consider such factors as, among other things, the share price from the investee's latest financing round, the performance of the investee in relation to its own operating targets and its business plan, the investee's revenue and cost trends, the liquidity and cash position, including its cash burn rate and market acceptance of the investee's products and services. Because these are private companies which we do not control we may not be able to obtain all of the information we would want in order to make a complete assessment of the investment on a timely basis. Accordingly, our estimates may be revised if other information becomes available at a later date.
Marketable Debt Securities
Marketable debt securities consist primarily of commercial paper, medium-term corporate notes, and U.S. government and agency backed securities. The Company classifies these marketable debt securities as available-for-sale at fair value in “Marketable debt securities, at fair value”. The Company's investment in GCS Holdings is included in "Other Assets" as available-for-sale and at fair value. The Company records the amortization of premium and accretion of discounts on marketable debt securities in the results of operations.
The Company uses the specific identification method as a basis for determining cost and calculating realized gains and losses with respect to marketable debt securities. The gross gains and losses realized related to sales and maturities of marketable debt securities were not material during the fiscal years ended 2018, 2017 and 2016.
Other-than-Temporary Impairments
The Company conducts a review of its marketable debt securities on a quarterly basis for the presence of other-than-temporary impairment ("OTTI"). The Company assesses whether OTTI is present when the fair value of a debt security is less than its amortized cost basis at the balance sheet date. Under these circumstances OTTI is considered to have occurred (1) if the Company intends to sell the security before recovery of its amortized cost basis; (2) if it is “more likely than not” the Company will be required to sell the security before recovery of its amortized cost basis; or (3) the present value of expected cash flows is not sufficient to recover the entire amortized cost basis.
The Company further estimates the amount of OTTI resulting from a decline in the creditworthiness of the issuer (credit-related OTTI) and the amount of non credit-related OTTI. Non credit-related OTTI can be caused by such factors as market illiquidity. Credit-related OTTI is recognized in earnings while non credit-related OTTI on securities not expected to be sold is recognized in other comprehensive income (loss). The Company did not record any OTTI for the fiscal years 2018, 2017 and 2016.
Stock-Based Compensation
The fair value of nonvested restricted common stock awards is generally the quoted price of the Company’s equity shares on the date of grant. The nonvested restricted common stock awards require the employee to fulfill certain obligations, including remaining employed by the Company for one, two or four years (the vesting period) and in certain cases also require meeting either performance criteria or market condition. The performance criteria primarily consist of the achievement of established milestones. For nonvested restricted common stock awards which solely require the recipient to remain employed with the Company, the stock compensation expense is amortized over the anticipated service period. For nonvested restricted common stock awards which require the achievement of performance criteria, the Company reviews the probability of achieving the performance goals on a periodic basis. If the Company determines that it is probable that the performance criteria will be achieved, the amount of compensation cost derived for the performance goal is amortized over the service period. If the performance criteria are not met, no compensation cost is recognized and any previously recognized compensation cost is reversed. The Company recognizes compensation costs on a straight-line basis over the requisite service period for time vested awards.
The value of restricted stock grants that vest based on market conditions is computed on the date of grant using the Monte Carlo model. The fair value of stock option awards is estimated on the date of grant using the Black-Scholes-Merton option-pricing model. There were no stock options granted in fiscal years 2018, 2017 or 2016.
Comprehensive Loss
Comprehensive loss is the total of net (loss) income and all other non-owner changes in equity including such items as unrealized holding (losses) gains on marketable equity and debt securities classified as available-for-sale and foreign currency translation adjustments.
The components of accumulated other comprehensive income are as follows:
 
Cumulative
Translation
Adjustment
 
Unrealized holding (loss) gain on marketable securities
 
Reclassifications of gain (loss) in net loss
 
Accumulated Other
Comprehensive
Income
Balance as of December 26, 2015
$
566,025

 
$
205,749

 
$

 
$
771,774

Changes during year
814,017

 
33,464

 
(48,284
)
 
799,197

Balance as of December 31, 2016
1,380,042

 
239,213

 
(48,284
)
 
1,570,971

Changes during year
1,851,664

 
148,520

 
(6,376
)
 
1,993,808

Balance as of December 30, 2017
3,231,706

 
387,733

 
(54,660
)
 
3,564,779

Changes during year
(1,794,768
)
 
(264,949
)
 
49,525

 
(2,010,192
)
Balance as of December 29, 2018
$
1,436,938

 
$
122,784

 
$
(5,135
)
 
$
1,554,587


Goodwill
We account for goodwill in accordance with ASC Topic 350. Under ASC Topic 350, goodwill is considered to have an indefinite life, and is carried at cost. Goodwill is not amortized, but is subject to an annual impairment test, as well as between annual tests when events or circumstances indicate that the carrying value may not be recoverable.
The determination of reporting units under ASC 350 begins with the definition of an operating segment in ASC 280 and takes into account the disaggregation of that operating segment into economically dissimilar components for goodwill impairment testing purposes. The level at which operating performance is reviewed also differs between ASC 280 and ASC 350. The chief operating decision maker ("CODM") is the Company's Chief Executive Officer who reviews operating segments and the segment manager reviews reporting units (components of operating segments). Therefore, a component of an operating segment would not be considered an operating segment under ASC 280 unless the CODM regularly reviews its operating performance. However, that same component might be a reporting unit under ASC 350 if a segment manager regularly reviews its operating performance (and if the other reporting unit criteria are met). Goodwill is evaluated for impairment annually or more often if indicators of a potential impairment are present. The Company performs impairment tests of goodwill at its reporting unit level. The goodwill valuations that are utilized to test these assets for impairment are depending on a number of significant estimates and assumptions, including macroeconomic conditions, overall growth rates, competitive activities, cost containment, Company business plans and the discount rate applied to cash flows. We believe these estimates and assumptions are reasonable and are comparable to those that would be used by other market participants. However, actual events and results could differ substantially from those used in our valuations. To the extent such factors result in a failure to achieve the level of projected cash flows initially used to estimate fair value for purposes of establishing the carrying amount of goodwill and intangibles, we may need to record non-cash impairment charges in the future.  
Impairment of Long-Lived Assets
The Company periodically reviews the carrying value of its long-lived assets to determine if facts and circumstances suggest that they may be impaired or that the amortization or depreciation period may need to be changed. The carrying value of a long-lived asset is considered impaired when the anticipated identifiable undiscounted cash flows from such asset are less than its carrying value. For assets that are to be held and used, impairment is measured based upon the amount by which the carrying amount of the asset exceeds its fair value.
Recently Issued Accounting Pronouncements
Leases
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize a right-of-use asset and lease liability for most lease arrangements. The new standard is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which allows for an additional transition method under the modified retrospective approach for the adoption of Topic 842. The two permitted transition methods are now: (1) to apply the new lease requirements at the beginning of the earliest period presented, and (2) to apply the new lease requirements at the effective date. Under both transition methods there is a cumulative effect adjustment. We intend to adopt the standard on the effective date of December 30, 2018 by applying the new lease requirements at the effective date. We also intend to elect the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allows us to carry forward the historical lease classification. We have evaluated the changes from this ASU to our future financial reporting and disclosures, and have designed and implemented related processes and controls to address these changes. We expect the standard will result in the recognition of right-of-use assets of $3.5 million to $4.0 million and lease liabilities of $3.5 million to $4.0 million as of December 30, 2018, with immaterial changes to other balance sheet accounts. The standard will have no impact on our results of operations or liquidity. In addition, new disclosures will be provided to enable users to assess the amount, timing and uncertainty of cash flows arising from leases.
Other new pronouncements issued but not effective until after December 29, 2018 are not expected to have a material impact on our financial position, results of operations or liquidity.
v3.19.1
Property, Plant and Equipment
12 Months Ended
Dec. 29, 2018
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Property, Plant and Equipment
Property, plant and equipment consisted of the following at December 29, 2018 and December 30, 2017:
 
Useful Life
 
2018
 
2017
Equipment
3-5 years
 
$
16,824,384

 
$
16,811,526

Leasehold improvements
Life of the lease
 
3,676,775

 
3,851,269

Furniture and fixtures
3 years
 
523,736

 
531,870

Equipment under construction
 
 
436,806

 
2,415,957

 
 
 
21,461,701

 
23,610,622

Accumulated depreciation and amortization
 
 
(18,862,859
)
 
(18,533,579
)
Property, plant and equipment, net
 
 
$
2,598,842

 
$
5,077,043


Depreciation expense for the fiscal years 2018, 2017 and 2016 was approximately $1.0 million, $0.9 million and $1 million, respectively.
During the fiscal year 2018, the Company recorded asset impairment charges of $2.5 million associated with equipment that either is not currently being utilized or will not be utilized for its remaining useful life and is not recoverable.
v3.19.1
Contract Assets and Liabilities (Notes)
12 Months Ended
Dec. 29, 2018
Contract Assets and Liabilities [Abstract]  
Contract Assets (Liabilities), Net [Text Block]
3.    Contract Assets and Liabilities
Net contract assets (liabilities) consisted of the following:
 
December 29, 2018
 
December 31, 2017
 
$ Change
 
% Change
Contract assets and unbilled receivables
$
3,089,663

 
$
3,555,137

 
$
(465,474
)
 
(13
)%
Contract liabilities and billings in excess of revenue earned
(388,933
)
 
(664,146
)
 
275,213

 
(41
)%
Contract liabilities, noncurrent
(17,294
)
 
(374,171
)
 
356,877

 
(95
)%
Net contract assets
$
2,683,436

 
$
2,516,820

 
$
166,616

 
7
 %

The $0.2 million increase in the Company's net contract assets from December 31, 2017 to December 29, 2018 was primarily due to our fixed-price contracts with the U.S. government that resulted in revenue recognized in excess of amounts billed and the adoption of Topic 606.
The Company recognized revenue of approximately $0.3 million and $0.4 million related to our contract liabilities at December 31, 2017 and January 1, 2017, respectively.
The Company did not recognize impairment losses on our contract assets during the years ended December 29, 2018 and December 30, 2017.
v3.19.1
Business Combinations
12 Months Ended
Dec. 29, 2018
Business Combinations [Abstract]  
Business Combinations
Business Combinations
In March 2017, we purchased 100% of the outstanding stock of NVIS, Inc. ("NVIS") for $3.7 million. NVIS produces virtual reality systems for 3D applications. Additional payments by the Company of up to $2.0 million may be required if certain future operating performance milestones are met and the selling shareholders remain employed with NVIS through March 2020. As there is a requirement to remain employed to earn the contingent payments, these contingent payments will be treated as compensation expense.
The identifiable assets acquired and liabilities assumed at the acquisition date have been recognized at fair value. The allocation of the purchase price as of the acquisition date is as follows:
Cash and marketable securities
$
2,600

Accounts receivable
490,700

Inventory
768,400

Other identifiable assets
46,800

Order backlog
840,000

Customer relationships
1,000,000

Developed technology
460,000

Trademark portfolio
160,000

Current liabilities
(480,500
)
Net deferred tax liabilities
(1,084,000
)
Goodwill
1,489,000

Total
$
3,693,000


Goodwill represents the recording of the excess of the purchase price over the fair values of the net tangible assets acquired. No significant adjustments were recorded to the purchase price allocation during the measurement period. During the fourth quarter of 2017, we finalized the fair values of the acquired assets and liabilities.
The identified intangible assets are being amortized on a straight-line basis over the following lives, in years:
Order backlog
1
Customer relationships
2
Developed technology
2
Trademark portfolio
2

In conjunction with the acquisition, the Company recorded deferred tax liabilities of approximately $1.1 million associated with the future non-deductible amortization of the intangible assets. These deferred tax liabilities can be used to offset the Company’s net deferred tax assets. The Company reduced the valuation allowance on its net deferred tax assets in the amount of $1.1 million and such reduction was recognized as a benefit for income taxes for 2017. Acquisition expenses were approximately $0.2 million for the fiscal year ended 2017 and were recorded in selling, general and administration expenses.
The following unaudited supplemental pro forma disclosures are provided for the fiscal year ended December 30, 2017. All intercompany transactions have been eliminated.
Fiscal year ended
 
2017
 
2016
Revenues
 
$
28,477,870

 
$
25,029,681

Net loss
 
(26,302,840
)
 
(23,736,518
)
Basic and diluted earnings per share
 
$
(0.38
)
 
$
(0.37
)
v3.19.1
Goodwill and Intangibles (Notes)
12 Months Ended
Dec. 29, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure [Text Block]
 Goodwill and Intangibles
A rollforward of the Company's goodwill by segment is as follows:
 
Kopin
 
Industrial
 
Total
Balance, December 31, 2016
$
844,023

 
$

 
$
844,023

March 2017 acquisition of NVIS, Inc.

 
1,488,650

 
1,488,650

Impairment of goodwill

 
(600,086
)
 
(600,086
)
Change due to exchange rate fluctuations
47,660

 

 
47,660

Balance, December 30, 2017
891,683

 
888,564

 
1,780,247

Impairment of goodwill
(528,906
)
 
(888,564
)
 
(1,417,470
)
Change due to exchange rate fluctuations
(31,433
)
 

 
(31,433
)
Balance, December 29, 2018
$
331,344

 
$

 
$
331,344


Goodwill is evaluated for impairment annually or more often if indicators of a potential impairment are present. The Company performs impairment tests of goodwill at its reporting unit level. The goodwill valuations that are utilized to test these assets for impairment are depending on a number of significant estimates and assumptions, including macroeconomic conditions, overall growth rates, competitive activities, cost containment, Company business plans and the discount rate applied to cash flows. We believe these estimates and assumptions are reasonable and are comparable to those that would be used by other market participants. However, actual events and results could differ substantially from those used in our valuations. To the extent such factors result in a failure to achieve the level of projected cash flows initially used to estimate fair value for purposes of establishing the carrying amount of goodwill, we may need to record non-cash impairment charges in the future.
At December 29, 2018, the Company performed an impairment analysis of goodwill based on a comparison of the discounted cash flows to the recorded carrying value of the reporting units, and determined that the discounted cash flows were not in excess of the carrying value of the NVIS reporting unit. At December 29, 2018, the Company decided to discontinue operations at its wholly-owned subsidiary, Kopin Software Ltd. and expects no future cash flows to support the carrying amount of goodwill. As a result, the Company recorded an impairment of goodwill of $1.4 million at December 29, 2018. The input methods for goodwill are analyzed for impairment on a nonrecurring basis using fair value measurements with unobservable inputs, which is Level 3 in the fair value hierarchy.
The Company recognized $0.9 million$1.6 million and $0.0 million in amortization expense for the fiscal years ended 20182017 and 2016, respectively, related to intangible assets. At December 29, 2018, the Company has a carrying value of $2.5 million and accumulated amortization of $2.5 million related to intangibles. The intangibles have no remaining useful life.
v3.19.1
Financial Instruments
12 Months Ended
Dec. 29, 2018
Financial Instruments [Abstract]  
Financial Instruments
Financial Instruments
Fair Value Measurements
Financial instruments are categorized as Level 1, Level 2 or Level 3 based upon the method by which their fair value is computed. An investment is categorized as Level 1 when its fair value is based on unadjusted quoted prices in active markets for identical assets that the Company has the ability to access at the measurement date. An investment is categorized as Level 2 if its fair market value is based on quoted market prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, based on observable inputs such as interest rates, yield curves, or derived from or corroborated by observable market data by correlation or other means. An investment is categorized as Level 3 if its fair value is based on assumptions developed by the Company about what a market participant would use in pricing the assets.
The following table details the fair value measurements of the Company’s financial assets:
 
 
 
Fair Value Measurement at December 29, 2018 Using:
 
Total
 
Level 1        
 
Level 2        
 
Level 3        
Cash and cash equivalents
$
14,326,347

 
$
14,326,347

 
$

 
$

U.S. government and agency backed securities
12,810,923

 

 
12,810,923

 

Corporate debt
10,107,093

 

 
10,107,093

 

GCS Holdings
288,026

 
288,026

 

 

Equity Investments
5,565,499

 

 

 
5,565,499

 
$
43,097,888

 
$
14,614,373

 
$
22,918,016

 
$
5,565,499

 
 
 
Fair Value Measurement at December 30, 2017 Using:
 
Total
 
Level 1        
 
Level 2        
 
Level 3        
Cash and cash equivalents
$
24,848,227

 
$
24,848,227

 
$

 
$

U.S. government and agency backed securities
34,725,811

 
6,927,323

 
27,798,488

 

Corporate debt
8,980,906

 

 
8,980,906

 

Certificates of deposit
200,740

 

 
200,740

 

GCS Holdings
478,546

 
478,546

 

 

Warrant
2,000,000

 

 

 
2,000,000

 
$
71,234,230

 
$
32,254,096

 
$
36,980,134

 
$
2,000,000


Transfers between levels of the fair value hierarchy are reported at the beginning of the reporting period in which they occur. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value because of their short-term nature. If accrued liabilities were carried at fair value, these would be classified as Level 2 in the fair value hierarchy.
Changes in Level 3 investments are as follows:
 
December 30, 2017
 
Net unrealized gains/(losses)
 
Purchases, issuances and settlements
 
Transfers in and or out of Level 3
 
December 29, 2018
Equity Investments
$

 
$
(284,317
)
 
$
5,849,816

 
$

 
$
5,565,499

Warrant
2,000,000

 
(50,184
)
 
(1,949,816
)
 

 

 
$
2,000,000

 
$
(334,501
)
 
$
3,900,000

 
$

 
$
5,565,499


Equity Investments
Equity investments rarely traded or not quoted will generally have less (or no) pricing observability and a higher degree of judgment utilized in measuring fair value. Initial measurement of equity investments occurs when an observable price for the equity investment is available. The Company adopted ASU No. 2016-01 and the related amendments on December 31, 2017 (the first day of the Company's fiscal year 2018). This standard amends various aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The Company adopted the measurement alternative for equity investments without readily determinable fair values (often referred to as cost method investments) on a prospective basis. As a result, these investments will be revalued upon occurrence of an observable price change for similar investments and for impairments.
Warrant
The Company had a warrant to acquire up to 15% of the next round of equity offered by a customer as part of the licensing of technology to the customer. The Company exercised the warrant in April 2018.
Marketable Debt Securities
The corporate debt consists of floating rate notes with a maturity that is over multiple years but has interest rates that are reset every three months based on the then-current three-month London Interbank Offering Rate ("three-month Libor"). The Company validates the fair market values of the financial instruments above by using discounted cash flow models, obtaining independent pricing of the securities or through the use of a model that incorporates the three-month Libor, the credit default swap rate of the issuer and the bid and ask price spread of the same or similar investments which are traded on several markets. Investments in available-for-sale marketable debt securities are as follows at December 29, 2018 and December 30, 2017: 
 
Amortized Cost
 
Unrealized Losses
 
Fair Value
 
2018
 
2017
 
2018
 
2017
 
2018
 
2017
U.S. government and agency backed securities
$
13,064,418

 
$
35,014,593

 
$
(253,495
)
 
$
(288,782
)
 
$
12,810,923

 
$
34,725,811

Corporate debt
10,175,084

 
8,988,608

 
(67,991
)
 
(7,702
)
 
10,107,093

 
8,980,906

Certificates of deposits

 
201,000

 

 
(260
)
 

 
200,740

Total
$
23,239,502

 
$
44,204,201

 
$
(321,486
)
 
$
(296,744
)
 
$
22,918,016

 
$
43,907,457


 
The contractual maturity of the Company’s marketable debt securities is as follows at December 29, 2018:
 
Less than
One year
 
One to
Five years
 
Total
U.S. government and agency backed securities
$
3,741,183

 
$
9,069,740

 
$
12,810,923

Corporate debt
2,709,074

 
7,398,019

 
10,107,093

Total
$
6,450,257

 
$
16,467,759

 
$
22,918,016

v3.19.1
Stockholders' Equity and Stock-Based Compensation
12 Months Ended
Dec. 29, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stockholders' Equity and Stock-Based Compensation
Stockholders’ Equity and Stock-Based Compensation
Sale of Unregistered Common Stock
On April 20, 2017, the Company sold 7,589,000 shares of unregistered common stock to Goertek, Inc. for $24,664,250 ($3.25 per share). This represented approximately 10.1% of Kopin’s total outstanding shares of common stock as of the date of purchase. In addition, Kopin and Goertek have entered into agreements to jointly develop and commercialize a range of technologies and wearable products. Goertek is a leading innovative global technology company headquartered in Weifang, China that designs and manufactures a range of consumer electronics products for brand customers including wearables, virtual and augmented reality headsets, and audio products. The transaction was accounted for under ASC 505-30 "Treasury Stock", and the loss on the sale of the treasury stock of approximately $0.8 million was charged to retained earnings. At completion of the transaction, the U.S. government requested certain information regarding the transaction for the Committee on Foreign Investment. See Note 16. Related Party Transactions for additional discussion around agreements with Goertek.
Restricted Stock Awards
In 2010, the Company adopted a 2010 Equity Incentive Plan ("2010 Equity Plan") which authorized the issuance of shares of common stock to employees, non-employees, and the Board. The 2010 Equity Plan was a successor to the Company’s 2001 Equity Incentive Plan ("2001 Equity Plan") and has been subsequently amended to increase the number of authorized shares to 14,100,000 as of December 29, 2018. The number of shares authorized under the 2010 Equity Plan is the number of shares approved by the shareholders plus the number of shares of common stock which were available for grant under the 2001 Equity Plan, the number of shares of common stock which were the subject of awards outstanding under the 2001 Equity Plan and are forfeited, terminated, canceled or expire after the adoption of the 2010 Equity Plan and the number of shares of common stock delivered to the Company either in exercise of an 2001 Equity Plan award or in satisfaction of a tax withholding obligation. The term and vesting period for restricted stock awards granted under the 2010 Equity Plan are determined by the Board’s compensation committee. As of December 29, 2018, the Company has approximately 1.7 million shares of common stock authorized and available for issuance under the Company’s 2010 Equity Plan.
The fair value of non-vested restricted common stock awards is generally the market value of the Company’s common stock on the date of grant. The non-vested restricted common stock awards require the employee to fulfill certain obligations, including remaining employed by the Company for one, two or four years (the vesting period) and in certain cases also require meeting either performance criteria or the Company’s stock achieving a certain price. For non-vested restricted common stock awards that solely require the recipient to remain employed with the Company, the stock compensation expense is amortized over the anticipated service period. For non-vested restricted common stock awards that require the achievement of performance criteria, the Company reviews the probability of achieving the performance goals on a periodic basis. If the Company determines that it is probable that the performance criteria will be achieved, the amount of compensation cost derived for the performance goal is amortized over the anticipated service period. If the performance criteria are not met, no compensation cost is recognized and any previously recognized compensation cost is reversed.
 
Shares
 
Weighted
Average
Grant
Fair Value
Outstanding at December 26, 2015
2,192,016

 
$
3.82

Granted
1,663,000

 
2.40

Forfeited
(110,500
)
 
3.21

Vested
(736,842
)
 
3.17

Outstanding at December 31, 2016
3,007,674

 
3.21

Granted
1,152,000

 
3.40

Forfeited
(465,150
)
 
3.82

Vested
(1,065,250
)
 
2.90

Balance at December 30, 2017
2,629,274

 
3.31

Granted
1,549,000

 
2.25

Forfeited
(872,025
)
 
3.78

Vested
(1,093,000
)
 
3.05

Balance at December 29, 2018
2,213,249

 
$
2.51


On December 31, 2017 (fiscal year beginning 2018), the Company amended the employment agreement with our CEO Dr. John Fan to expire on December 31, 2020 and as part of the amendment issued restricted stock grants. 640,000 shares of restricted stock which will vest upon the first 20 consecutive trading day period following the grant date during which the Company's common stock trades at a price equal to or greater than $5.25150,000 shares of restricted stock will vest at the end of the first 20 consecutive trading day period following the grant date during which the Company’s common stock trades at a price per share equal to or greater than $6.00, and 150,000 shares of restricted common stock will vest at the end of the first 20 consecutive trading day period following the grant date during which the Company’s common stock trades at a price per share equal to or greater than $7.00. All of the grants are subject to certain acceleration events and terminate on December 31, 2020.
 
For the period ended December 29, 2018
Performance price target
$
5.25

 
$
6.00

 
$
7.00

Expected volatility
48.3
%
 
48.3
%
 
48.3
%
Interest rate
1.97
%
 
1.97
%
 
1.97
%
Expected life (years)
2

 
2

 
2

Dividend yield
%
 
%
 
%
Stock-Based Compensation
The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the fiscal years 2018, 2017 and 2016 (no tax benefits were recognized):
 
2018
 
2017
 
2016
Cost of product revenues
$
418,605

 
$
490,481

 
$
561,791

Research and development
725,112

 
799,485

 
527,081

Selling, general and administrative
3,647,337

 
1,006,165

 
1,336,454

Total
$
4,791,054

 
$
2,296,131

 
$
2,425,326


Unrecognized compensation expense for non-vested restricted common stock as of December 29, 2018 totaled $3.4 million and is expected to be recognized over a weighted average period of approximately two years.
v3.19.1
Concentrations of Risk
12 Months Ended
Dec. 29, 2018
Risks and Uncertainties [Abstract]  
Concentrations of Risk
Concentrations of Risk
Ongoing credit evaluations of customers’ financial condition are performed and collateral, such as letters of credit, are generally not required. Customer’s accounts receivable balance as a percentage of total accounts receivable was as follows:
 
Percent of Gross
Accounts Receivable
Customer
December 29,
2018
 
December 30,
2017
Collins Aerospace
11%
 
*
DRS Technologies
11%
 
*
Scott Safety
*
 
14%
RealWear, Inc.
31%
 
10%
U.S. Army
*
 
43%
Note: The symbol “*” indicates that accounts receivables from that customer were less than 10% of the Company’s total accounts receivable.
Sales to significant non-affiliated customers for fiscal years 2018, 2017 and 2016, as a percentage of total revenues, is as follows:
 
Sales as a Percent
of Total Revenue
 
Fiscal Year
Customer
2018
 
2017
 
2016
Military Customers in Total
36%
 
48%
 
24%
General Dynamics
11%
 
*
 
*
DRS Technologies
*
 
10%
 
*
Collins Aerospace
20%
 
10%
 
12%
Shenzhen Oriscape
*
 
*
 
20%
U.S. Army
*
 
12%
 
*
Funded Research and Development Contracts
20%
 
11%
 
7%

Note: The symbol “*” indicates that sales to that customer were less than 10% of the Company’s total revenues. The caption "Military Customers in Total" excludes research and development contracts.
v3.19.1
Income Taxes
12 Months Ended
Dec. 29, 2018
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The (benefit) provision for income taxes from continuing operations consists of the following for the fiscal years indicated: 
 
Fiscal Year
 
2018
 
2017
 
2016
Current
 
 
 
 
 
State
$
5,000

 
$
5,000

 
$
33,000

Foreign
25,000

 
(568,000
)
 
1,656,000

Total current provision
30,000

 
(563,000
)
 
1,689,000

Deferred
 
 
 
 
 
Federal
(7,307,000
)
 
15,461,000

 
(8,718,000
)
State
(360,000
)
 
(493,000
)
 
(1,264,000
)
Foreign
300,000

 
(187,000
)
 
2,308,000

Change in valuation allowance
7,367,000

 
(17,181,000
)
 
9,115,000

Total (benefit) deferred provision

 
(2,400,000
)
 
1,441,000

Total provision (benefit) for income taxes
$
30,000

 
$
(2,963,000
)
 
$
3,130,000


The following table sets forth the changes in Kopin's balance of unrecognized tax benefits for the year ended:

Total
Unrecognized tax benefits at December 26, 2016
$
374,000

Gross increases—prior year tax positions
20,000

Unrecognized tax benefits at December 30, 2017
394,000

Gross increases—current year tax positions

Unrecognized tax benefits at December 29, 2018
$
394,000


U.S. GAAP requires applying a 'more likely than not' threshold to the recognition and derecognition of uncertain tax positions either taken or expected to be taken by Kopin's income tax returns. The total amount of our gross tax liability for tax positions that may not be sustained under a 'more likely than not' threshold amounts to $0.4 million as of December 29, 2018 and December 30, 2017. Kopin's policy regarding the classification of interest and penalties is to include these amounts as a component of income tax expense. The total amount of accrued interest and penalties related to the Company's unrecognized tax benefits was $0.5 million as of December 29, 2018 and December 30, 2017.
Net operating losses were not utilized in 2018, 2017 and 2016 to offset federal and state taxes.
The actual income tax (benefit) provision reported from operations are different than those which would have been computed by applying the federal statutory tax rate to loss before income tax (benefit) provision. A reconciliation of income tax (benefit) provision from continuing operations as computed at the U.S. federal statutory income tax rate to the provision for income tax benefit is as follows:
 
Fiscal Year
 
2018
 
2017
 
2016
Tax provision at federal statutory rates
$
(7,515,000
)
 
$
(9,884,000
)
 
$
(6,965,000
)
State tax liability
5,000

 
5,000

 
22,000

Foreign deferred tax rate differential
(39,000
)
 
15,000

 
(678,000
)
Foreign withholding
301,000

 
(771,000
)
 
1,441,000

Outside basis in Kowon, net unremitted earnings
(468,000
)
 
(2,888,000
)
 
958,000

Permanent items
186,000

 
774,000

 
259,000

Increase in net state operating loss carryforwards
(406,000
)
 
(300,000
)
 
(502,000
)
Utilization of net operating losses for U.K. research and development refund

 

 
(142,000
)
Provision to tax return adjustments and tax rate change (1)
(76,000
)
 
24,833,000

 
(66,000
)
Tax credits
239,000

 
24,000

 
(762,000
)
Non-deductible 162M compensation limitations
13,000

 
199,000

 

Non-deductible equity compensation
290,000

 
1,901,000

 
(360,000
)
Uncertain tax position for transfer pricing
91,000

 
203,000

 
671,000

Other, net
45,000

 
107,000

 
139,000

Change in valuation allowance
7,364,000

 
(17,181,000
)
 
9,115,000

 
$
30,000

 
$
(2,963,000
)
 
$
3,130,000


(1)
Due to the Tax Act which was enacted in December 2017, our U.S. deferred tax assets and liabilities as of December 30, 2017 were re-measured to 21%. The provisional amount recorded related to the remeasurement of our deferred tax balance was approximately $25.1 million of tax expense.
Pretax foreign income from continuing operations was approximately $0.7 million for fiscal year ended 2018, pretax foreign loss from continuing operations was approximately $0.4 million for fiscal year ended 2017 and pretax foreign income from continuing operations was approximately $5.4 million for fiscal year ended 2016. Deferred income taxes are provided to recognize the effect of temporary differences between tax and financial reporting. Deferred income tax assets and liabilities consist of the following: 
 
Fiscal Year
 
2018
 
2017
Deferred tax liability:
 
 
 
Foreign withholding liability
$
(538,000
)
 
$
(812,000
)
Foreign unremitted earnings

 
(468,000
)
Intangible assets

 
(259,000
)
Deferred tax assets:
 
 
 
Federal net operating loss carryforwards
41,755,000

 
34,555,000

State net operating loss carryforwards
3,114,000

 
2,708,000

Foreign net operating loss carryforwards
1,259,000

 
1,500,000

Equity awards
444,000

 
55,000

Tax credits
7,231,000

 
7,470,000

Property, plant and equipment
640,000

 
544,000

Unrealized losses on investments
1,848,000

 
1,792,000

Other
1,707,000

 
3,037,000

Net deferred tax assets
57,460,000

 
50,122,000

Valuation allowance
(58,006,000
)
 
(50,642,000
)
 
$
(546,000
)
 
$
(520,000
)

The valuation allowance was approximately $58.0 million and $50.6 million at December 29, 2018 and December 30, 2017, respectively, primarily driven by U.S. net operating loss carryforwards ("NOLs") and tax credits that the Company does not believe will ultimately be realized.
On December 22, 2017, the President signed the Tax Cuts and Jobs Act of 2017 ("2017 Act") which enacted a wide range of changes to the U.S. corporate income tax system. The 2017 Act reduced the U.S. corporate statutory federal tax rate to 21% effective in 2018, eliminated the domestic manufacturing deduction benefit and introduced other tax base broadening measures, changed rules for expensing and capitalizing business expenditures, established a territorial tax system for foreign earnings as well as a minimum tax on certain foreign earnings, provided for a one-time transition tax on previously undistributed foreign earnings, and introduced new rules for the treatment of certain foreign income. Also on December 22, 2017, the Securities and Exchange Commission (SEC) issued Staff Accounting Bulletin No. 118 (SAB 118), which provided companies with additional guidance on how to account for the 2017 Act in their financial statements, allowing companies to use a measurement period. As of December 30, 2017, we made a reasonable estimate of the effects on our existing deferred tax balances and the one-time transition tax on previously undistributed foreign earnings and the Company did not recognize any provisional amounts in the (benefit) provision for income taxes in accordance with SAB 118. As of December 29, 2018, we had finalized our provisional estimates for the remeasurement of our existing U.S. deferred tax balances and the one-time transition tax and did not recognize amounts in the (benefit) provision for income taxes.
Deferred tax assets and liabilities—The Company has remeasured certain deferred tax assets and liabilities, excluding those items that will be included on the Company's 2017 tax return, based on the rates the Company expects to realize the deferred tax assets and liabilities at in the future, which is generally 21%. The amount recorded related to the remeasurement of the Company's deferred tax balance was approximately $25.1 million of tax expense. At December 29, 2018, we have finalized our provisional estimate for the remeasurement of our existed deferred tax balances with no additional adjustment.
The Company recorded a reduction in the valuation allowance during 2017 of approximately $1.0 million which was previously recorded against the Company’s AMT credit. The Company expects to receive a refund of $1.0 million from our AMT credit in accordance with the Tax Act and have recorded the receivable in "Other assets" on the Company's consolidated balance sheets at December 29, 2018.
In addition to the changes described above, the 2017 Act imposes a U.S. tax on global intangible low taxed income ("GILTI") that is earned by certain foreign affiliates owned by a U.S. shareholder. The computation of GILTI is generally intended to impose tax on the earnings of a foreign corporation that are deemed to exceed a certain threshold return relative to the underlying business investment. The Company has made a policy election to treat future taxes related to GILTI as a current period expense in the reporting period in which the tax is incurred.
Foreign tax effects—The one-time transition tax is based on our total post-1986 earnings and profits (“E&P”) for which the Company has previously deferred U.S. income taxes. The Company is estimating that the Company will not have a provisional requirement amount for our one-time transition tax liability, using an estimated applicable tax rate of 15.5%, resulting in no increase in income tax expense. The Company has not yet completed our calculation of the total post-1986 foreign E&P for these foreign subsidiaries. Further, the transition tax is based in part on the amount of those earnings held in cash and other specified assets. This amount may change when the Company finalizes the calculation of post-1986 foreign E&P previously deferred from U.S. federal taxation and finalize the amounts held in cash or other specified assets. The Company also expects additional clarifying and interpretative technical guidance to be issued related to the calculation of our one-time transition tax. No additional income taxes have been provided for any remaining undistributed foreign earnings not subject to the transition tax and any additional outside basis difference inherent in these entities as these amounts continue to be indefinitely reinvested in foreign operations.
As of December 29, 2018, the Company has available for tax purposes NOLs of $198.8 million expiring 2022 through 2037. The Company has recognized a full valuation allowance on its net deferred tax assets as the Company has concluded that such assets are not more likely than not to be realized. The decrease in valuation allowance during fiscal year 2018 was a result of decreases in the federal tax rate as part of the Tax Act and a reduction in the valuation allowance as a result of deferred tax liabilities assumed as part of the acquisition of NVIS.
The Tax Act imposes a mandatory transition tax on accumulated foreign earnings and eliminates U.S. taxes on foreign subsidiary distribution. As a result, earnings in foreign jurisdictions are available for distribution to the U.S. without incremental U.S. taxes.
Under the provisions of Section 382, certain substantial changes in Kopin’s ownership may limit in the future the amount of net operating loss carryforwards that could be used annually to offset future taxable income and income tax liability.
The Company’s income tax returns have not been examined by the Internal Revenue Service and are subject to examination for all years since 2001. State income tax returns are generally subject to examination for a period of three to five years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to one year after formal notification to the states.
International jurisdictions have statutes of limitations generally ranging from three to twenty years after filing of the respective return. Years still open to examination by tax authorities in major jurisdictions include Korea (2009 onward), Japan (2009 onward), Hong Kong (2011 onward) and United Kingdom (2014 onward). The Company is not currently under examination in these jurisdictions.
v3.19.1
Accrued Warranty
12 Months Ended
Dec. 29, 2018
Product Warranties Disclosures [Abstract]  
Accrued Warranty
Accrued Warranty
The Company warrants its products against defect for 12 months, however, for certain products a customer may purchase an extended warranty. A provision for estimated future costs and estimated returns for credit relating to such warranty is recorded in the period when product is shipped and revenue recognized, and is updated as additional information becomes available. The Company’s estimate of future costs to satisfy warranty obligations is based primarily on historical warranty expense experienced and a provision for potential future product failures. Changes in the accrued warranty for fiscal years ended 2018, 2017 and 2016 are as follows:
 
Fiscal Year Ended
 
December 29,
2018
 
December 30,
2017
 
December 31,
2016
Beginning balance
$
649,000

 
$
518,000

 
$
518,000

Additions
159,000

 
328,000

 
440,000

Claim and reversals
(237,000
)
 
(197,000
)
 
(440,0